Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Walter E. DeWolf"'
Autor:
David M. Hyman, S. Michael Rothenberg, Steve Andrews, Barry S. Taylor, Jaclyn F. Hechtman, Michael F. Berger, Philip Jonsson, Alison M. Schram, Bethany Hanusch, Sandeep Raj, Ryma Benayed, Maurizio Scaltriti, Dorothea N. Douglas-Lindsay, Paul R. Gordon, Lance A. Wollenberg, Walter E. DeWolf, Francis X. Sullivan, Tony H. Morales, Andrew Parker, Wen-I Wu, Robyn Hamor, Shannon L. Winski, Karyn S. Bouhana, Paul D. Larsen, Barbara J. Brandhuber, Gabrielle R. Kolakowski, Veronique Lauriault, Steve Smith, Kevin Ebata, Brian B. Tuch, Nora Ku, James F. Blake, Ramamoorthy Nagasubramanian, Alexander Drilon
Supplementary Methods Supplementary References Supplementary Figure 1. Effect of acquired resistance mutations on TRK inhibitor activity. Supplementary Figure 2. Further characterization of LOXO-195 inhibitory activity against acquired resistance mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5cf7abc92430333d360a2e3d9ce4f70
https://doi.org/10.1158/2159-8290.22532260
https://doi.org/10.1158/2159-8290.22532260
Autor:
Min Lu, Pingping Li, Gautam Bandyopadhyay, William Lagakos, Walter E Dewolf, Taylor Alford, Mark Joseph Chicarelli, Lance Williams, Deborah A Anderson, Brian R Baer, Maralee McVean, Marion Conn, Murielle M Véniant, Peter Coward
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e88431 (2014)
Glucokinase (GK) is a hexokinase isozyme that catalyzes the phosphorylation of glucose to glucose-6-phosphate. Glucokinase activators are being investigated as potential diabetes therapies because of their effects on hepatic glucose output and/or ins
Externí odkaz:
https://doaj.org/article/6b5ff3c689ce4246a24878968b2d01da
Autor:
Dylan P. Hartley, Suzy Brown, Karyn Bouhana, Walter E. DeWolf, Jay Brad Fell, Li Ren, Patrice Lee, David A. Moreno, Ross D. Wallace, Deborah A. Anderson, Lance Williams
Publikováno v:
Cancer Research. 81:1473-1473
Although approved BRAF inhibitors have transformed the treatment of patients with certain BRAF V600 mutant cancers, their long-term efficacy is thought to be limited by poor brain penetration. As a result, disease progression in the brain is a signif
Autor:
Scott Alan Pratt, Patrice Lee, Thomas Daniel Aicher, John Fischer, Kevin Ronald Condroski, Brian R. Baer, Boyd Steven A, Mark D. Chicarelli, Walter C. Voegtli, Walter E. DeWolf, Francis X. Sullivan, Eli M. Wallace, Nickolas A. Neitzel, Lance A. Williams, Ronald Jay Hinklin, Turner Timothy M, Ajay Singh, Gary P. Hingorani, Michele Frank
Publikováno v:
Bioorganicmedicinal chemistry. 28(1)
Glucose flux through glucokinase (GK) controls insulin release from the pancreas in response to high levels of glucose. Flux through GK is also responsible for reducing hepatic glucose output. Since many individuals with type 2 diabetes appear to hav
Autor:
Kevin Ronald Condroski, Susan P. Rhodes, Maralee McVean, Walter C. Voegtli, Christopher F. Kraser, Walter E. DeWolf, Lance A. Williams, Deborah Anderson, Hillary L. Sturgis, Boyd Steven A, Ronald Jay Hinklin, Jonathan B. Houze, Brian R. Baer, Thomas Daniel Aicher
Publikováno v:
Journal of Medicinal Chemistry. 57:8180-8186
Glucokinase (GK) is the rate-limiting step for insulin release from the pancreas in response to high levels of glucose. Flux through GK also contributes to reducing hepatic glucose output. Since many individuals with type 2 diabetes appear to have an
Autor:
Ajay Singh, Lee Wai-Man, Kevin Ronald Condroski, Patrice Lee, Thomas Daniel Aicher, Laurie Thomas, Ronald Jay Hinklin, Boyd Steven A, Mark Joseph Chicarelli, Walter E. DeWolf, Lance Williams, Walter C. Voegtli
Publikováno v:
Journal of Medicinal Chemistry. 56:7669-7678
Glucose flux through glucokinase (GK) controls insulin release from the pancreas in response to high glucose concentrations. Glucose flux through GK also contributes to reducing hepatic glucose output. Because many individuals with type 2 diabetes ap
Autor:
Barb Brandhuber, Stephen S. Gonzales, Guy Vigers, Kevin Ronald Condroski, Jed Pheneger, Patrice Lee, Allen A. Thomas, Y. Le Huerou, J. De Meese, Robin Pedersen, Jie Lin, Todd Romoff, Greg Poch, Christine Lemieux, Gunawardana Indrani W, Boyd Steven A, May Han, Francis X. Sullivan, Darin Smith, Bryan Bernat, Tomas Kaplan, Walter E. DeWolf, Josh Ballard, S. Kirk Wright, Solly Weiler
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:2206-2210
Tumor cells extensively utilize the pentose phosphate pathway for the synthesis of ribose. Transketolase is a key enzyme in this pathway and has been suggested as a target for inhibition in the treatment of cancer. In a pharmacodynamic study, nude mi
Autor:
Allen A. Thomas, Todd Romoff, Laura Hayter, Jed Pheneger, Jason De Meese, Patrice Lee, Boyd Steven A, S. Kirk Wright, Christine Lemieux, Gunawardana Indrani W, Steven S. Gonzales, Walter E. DeWolf, Francis X. Sullivan, Yvan Le Huerou, Jie Lin, Gregory K. Poch, May Han, Tomas Kaplan, Solly Weiler
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:505-508
Transketolase, a key enzyme in the pentose phosphate pathway, has been suggested as a target for inhibition in the treatment of cancer. Compound 5a ('N3'-pyridyl thiamine'; 3-(6-methyl-2-amino-pyridin-3-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-
Autor:
William H. Miller, Frank Fan, Nicola G. Wallis, Mark A. Seefeld, Walter E. DeWolf, Martha S. Head, David J. Payne, Damien McDevitt, Jianzhong Huang, Terrance D. Moore, Dalia R. Jakas, Kenneth A. Newlander, Kang Yan, Stephen Rittenhouse, Shannon L. Reed
Publikováno v:
Antimicrobial Agents and Chemotherapy. 46:3343-3347
The MICs of triclosan for 31 clinical isolates of Staphylococcus aureus were 0.016 μg/ml (24 strains), 1 to 2 μg/ml (6 strains), and 0.25 μg/ml (1 strain). All the strains for which triclosan MICs were elevated (>0.016 μg/ml) showed three- to fiv
Autor:
William H. Miller, Catherine C.K. Yuan, Kalindi Vaidya, Brian J. Polizzi, Dennis T. Takata, Rebecca Claire Greenwood, Dirk A. Heerding, Mark A. Seefeld, Scott B. Winram, Valerie Berry, Martha S. Head, Walter J. Burgess, Andrew P. Fosberry, Nicola G. Wallis, David J. Payne, Stephen Rittenhouse, William F. Huffman, Paul M. Keller, Kevin L. Salyers, Manley Peter J, Kenneth A. Newlander, Deborah Dee Jaworski, Courtney Slater-Radosti, Cheryl A. Janson, Walter E. DeWolf, Irene N. Uzinskas, John Brosky, Stewart C. Pearson, Xiayang Qiu, Emile Chen, Terrance D. Moore, Martin G. Smyth
Publikováno v:
Antimicrobial Agents and Chemotherapy. 46:3118-3124
Bacterial enoyl-acyl carrier protein (ACP) reductase (FabI) catalyzes the final step in each elongation cycle of bacterial fatty acid biosynthesis and is an attractive target for the development of new antibacterial agents. High-throughput screening